Household pollution and obstructive diseases: asthma and COPD
J. Chatkin (Porto Alegre (RS), Brazil)
|   |
E-cigarettes and smoking cessation: the evidence or the non-evidence
C. Pisinger (Frederiksberg, Denmark)
| |
The impact of anti-IgE treatment on the airway microbiome in asthma.
A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland)
|   |
Maternal and perinatal obesity arrests alveolarization and reduces alveolar progenitor cells in offspring
J. Selle (Cologne, Germany), K. Dinger (Cologne, Germany), H. Kesler (Cologne, Germany), T. Georgomanolis (Cologne, Germany), C. Vohlen (Cologne, Germany), R. Wilke (Cologne, Germany), J. Dötsch (Cologne, Germany), M. Alejandre Alcazar (Cologne, Germany)
| |
Plasmacytoma
C. Ortega Michel (San Sebastian, Spain)
| |
Pulmonary functional diagnosis of COPD
Z. Aisanov (Moscow, Russian Federation)
| |
Classification of COPD: problems and controversies
K. Kostikas (Ioannina, Greece)
| |
Pathomorphology of COPD
M. Samsonova (Moscow, Russian Federation)
| |
Histopathological comparison of endobronchial biopsies from different pulmonary lobes of severe asthmatic patients
M. Karakioulaki (Basel, Switzerland), T. Koletsa (Thessaloniki, Greece), E. Papakonstantinou (Basel, Switzerland), S. Savic (Basel, Switzerland), K. Jahn (Basel, Switzerland), M. Tamm (Basel, Switzerland), D. Stolz (Basel, Switzerland)
| |
Categorization of asthma patients by Global Initiative for Asthma (GINA) 2018 guidelines using a US administrative claims database
M. Castro (Kansas City, United States of America), M. Mychaskiw (West Chester, United States of America), S. Lim (West Chester, United States of America), R. Brown (West Chester, United States of America), S. Colilla (West Chester, United States of America)
| |
Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands)
| |
Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify asthma-COPD overlap
T. Shirai (Shizuoka, Japan), K. Hirai (Shizuoka, Japan), Y. Gon (Tokyo, Japan), S. Maruoka (Tokyo, Japan), K. Mizumura (Tokyo, Japan), M. Hikichi (Tokyo, Japan), K. Itoh (Shizuoka, Japan), S. Hashimoto (Tokyo, Japan)
| |
Early-life exposure to air pollution and lung function development into adolescence: the GINIplus/LISA birth cohorts
Q. ZHAO (Düsseldorf, Germany), I. Markevych (Krakow, Poland), D. Berdel (Wesel, Germany), A. Berg (Wesel, Germany), M. Gappa (Düsseldorf, Germany), S. Koletzko (Munich, Germany), C. Bauer (Munich, Germany), H. Schulz (Neuherberg, Germany), M. Standl (Neuherberg, Germany), J. Heinrich (Neuherberg, Germany), T. Schikowski (Düsseldorf, Germany)
| |
Pollen exposure in pregnancy and infancy and risk of childhood asthma
C. Lundholm (Stockholm, Sweden), C. Almqvist (Stockholm, Sweden), S. Ekberg (Stockholm, Sweden), F. Fang (Stockholm, Sweden), T. Fall (Uppsala, Sweden), Å. Dahl (Göteborg, Sweden)
| |
Respiration monitoring in COPD patients
D. Blanco-Almazán (Barcelona, Spain)
| |
Activation of toxicology-related genes in human airway constructs after exposure to indoor air particulate matter from moisture-damaged houses
M. Nordberg (Kuopio, Finland), M. Täubel (Kuopio, Finland), H. Leppänen (Kuopio, Finland), A. Hyvärinen (Kuopio, Finland), K. Huttunen (Kuopio, Finland)
| |
Identification and characterisation of twenty-two novel SERPINA1 pathological mutations
S. Ottaviani (Pavia (PV), Italy), A. Fra (Brescia (BS), Italy), A. Balderacchi (Pavia (PV), Italy), V. Barzon (Pavia (PV), Italy), T. Carroll (Dublin, Ireland), D. Piloni (Pavia (PV), Italy), F. Mariani (Pavia (PV), Italy), N. Mc Elvaney (Dublin, Ireland), A. Corsico (Pavia (PV), Italy), I. Ferrarotti (Pavia (PV), Italy)
| |
Interaction between VGDF exposure and antioxidant genes on COPD in UK Biobank
D. van der Plaat (London, United Kingdom), S. De Matteis (Cagliari, Italy), S. Sadhra (Birmingham, United Kingdom), D. Jarvis (London, United Kingdom), P. Cullinan (London, United Kingdom), C. Minelli (London, United Kingdom)
| |
Risques cardiovasculaires et BPCO / Cardiovascular risks and COPD
B. Degano (grenoble, France)
| |
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), É. Mateus Medina (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), S. Quirce Gancedo (Madrid, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain)
| |
Changes in DNA methylation after corticosteroids treatment in COPD patients
J. van Nijnatten (Groningen, Netherlands), C. Brandsma (Groningen, Netherlands), P. Hiemstra (Leiden, Netherlands), W. Timens (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands), A. Faiz (Sydney, Australia)
| |
Azithromycin prevents airway epithelial barrier dysfunction induced by sulphur dioxide inhalation
J. Kricker (REYKJAVIK, Iceland), T. Gudjonsson (REYKJAVIK, Iceland), A. Arason (REYKJAVIK, Iceland), J. Joelsson (REYKJAVIK, Iceland), B. Valdimarsdottir (REYKJAVIK, Iceland), F. Gardarsson (REYKJAVIK, Iceland), C. Page (LONDON, United Kingdom), F. Lehmann (REYKJAVIK, Iceland), S. Ingthorsson (REYKJAVIK, Iceland)
| |
Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics.
P. Daley-Yates (Uxbridge, United Kingdom), B. Keppler (Morrisville, United States of America), N. Brealey (Uxbridge, United Kingdom), S. Shabbir, (Stevenage, United Kingdom), D. Singh (Manchester, United Kingdom), N. Barnes (Brentford, United Kingdom)
| |
Lung microbial factors as drivers for COPD
M. Hilty (Bern, Switzerland)
| |
Bacterial dysbiosis in pediatric lung diseases such as asthma and CF
A. Dalpke (Dresden, Germany)
| |
Cellular senescence in regeneration and diseases of the lung
M. Lehmann (München, Germany)
| |
Senescence and immune ageing
M. Rojas (Pittsburgh, United States of America)
| |
Targeting the lung epithelium: does age matter?
P. Wolters (San Francisco, United States of America)
| |
Severe asthma guidelines: 2019 update
R. Buhl (Mainz, Germany)
| |
ICS discontinuation guidelines in COPD
D. Stolz (Basel, Switzerland)
| |
Mitochondrial iron in the susceptibility, pathogenesis and progression of COPD
S. Cloonan (New York City, United States of America)
| |
Sing-a-Lung: Group singing as training modality in pulmonary rehabilitation for patients with Chronic Obstructive Pulmonary Disease (COPD): A multicenter, cluster-randomised, non-inferiority controlled trial
M. Kaasgaard (Copenhagen, Denmark), D. Bech Rasmussen (Naestved, Denmark), A. Løkke Ottesen (Vejle, Denmark), P. Vuust (Aarhus, Denmark), O. Hilberg (Vejle, Denmark), U. Bodtger (Naestved, Denmark)
| |
Spirometric phenotypes from early childhood to young adulthood – A CADSET (Chronic Airway Disease Early Stratification) study
E. Melén (Stockholm, Sweden), J. Hallberg (Stockholm, Sweden), H. Backman (Umeå, Sweden), E. Baraldi (Padova, Italy), R. Breyer-Kohansal (Vienna, Austria), M. Casas (Barcelona, Spain), F. Chung (London, United Kingdom), L. Duijts (Rotterdam, Netherlands), R. Granell (Bristol, United Kingdom), T. Sigsgaard (Aarhus, Denmark), M. Van Der Berge (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), E. Heuvelin (Lausanne, Switzerland), R. Faner (Barcelona, Spain), G. Donaldson (London, United Kingdom), J. Wedzicha (London, United Kingdom), A. Agusti (Barcelona, Spain), A. Maitland Van Der Zee (Amsterdam, Netherlands)
| |
Does the endotype-driven approach translate into improved quality of life?
B. Flood (Gorey, Ireland)
| |
Linking clinical algorithms to precision medicine
M. Bonini (Rome, Italy)
| |
Upper airways in asthmatic patients
A. Bossios (Stockholm, Sweden)
| |
High-dimensional multivariable analysis of asthma and its co-morbidities
B. Schaub (Munich, Germany)
| |
Allergy testing and immunotherapy guidelines
I. Agache (Brasov (Brasov), Romania)
| |
Wrap-up by discussant and discussion
M. Gaga (Athens, Greece)
| |
Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm
T. Hardman (Kingston-Upon-Thames, United Kingdom), L. Heaney (Belfast, United Kingdom), J. Busby (Belfast, United Kingdom), C. Hanratty (Belfast, United Kingdom), R. Djukanovic (Southampton, United Kingdom), A. Woodcock (Manchester, United Kingdom), S. Walker (London, United Kingdom), J. Arron (California,, United States of America), D. Choy (California, United States of America), P. Bradding (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), D. Cowan (Glasgow, United Kingdom), R. Niven (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom), T. Harrison (Nottingham, United Kingdom), P. Howarth (Southampton, United Kingdom), J. Lordan (Newcastle, United Kingdom), A. Mansur (Birmingham, United Kingdom), A. Menzies-Gow (London, United Kingdom), D. Robinson (London, United Kingdom)
| |
Effect of controller prescribing according to rs1042713 genotype on asthma related quality of life in young people (PACT): a randomized controlled trial
T. Ruffles (Brighton, United Kingdom), C. Jones (Guildford, United Kingdom), C. Palmer (Dundee, United Kingdom), S. Turner (Aberdeen, United Kingdom), J. Grigg (London, United Kingdom), R. Tavendale (Dundee, United Kingdom), F. Hogarth (Dundee, United Kingdom), P. Rauchhaus (Dundee, United Kingdom), K. Pilvinyte (Dundee, United Kingdom), H. Smith (Brighton, United Kingdom), R. Littleford (Brisbane, Australia), B. Lipworth (Dundee, United Kingdom), S. Mukhopadhyay (Brighton, United Kingdom)
| |
Modeling the regenerative potential of airway epithelial cells
P. Hiemstra (Leiden, Netherlands)
| |
Is it more than just asthma?
M. Proesmans (Leuven, Belgium)
| |
Non-invasive ventilation can modulate the responses of vascular reactivity in COPD-HF patients to high-intensity exercise
C. Goulart (São Carlos, Brazil), F. Caruso (São Carlos, Brazil), A. Araújo (São Carlos, Brazil), P. Santos (São Carlos, Brazil), G. Arêas (São Carlos, Brazil), G. Casale (São Carlos, Brazil), R. Mendes (São Carlos, Brazil), A. Da Silva (Santa Cruz do Sul, Brazil), A. Borghi-Silva (São Carlos, Brazil)
| |
Exertional dyspnea in COPD: the dominant role of increased diaphragmatic activation
. James (Kingston, Canada), K. Milne (Kingston, Canada), M. Ibrahim Masthan (Kingston, Canada), J. Neder (Kingston, Canada), D. O'Donnell (Kingston, Canada)
| |
Oxygen uptake measured at the ventilatory threshold is a mortality marker in COPD
T. Georges (Nantes, France), S. Courat (Nantes, France), M. Le Vaillant (Beaucouzé, France), H. Ouksel (Beaucouzé, France), A. Chambellan (Nantes, France)
| |
Acute health effects after passive e-vape among patients with COPD – an RCT exposure study
K. Rosenkilde Laursen (Aarhus, Denmark), J. H. Bønløkke (Ålborg, Denmark), M. Bilde (Aarhus, Denmark), M. Glasius (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), S. K. Kjærgaard (Aarhus, Denmark), A. Olin (Gothenburg, Sweden), T. Sigsgaard (Aarhus, Denmark)
| |
Asthma do not counteract smoking initiation
L. Hedman (Umeå, Sweden), H. Backman (Umeå, Sweden), M. Andersson (Umeå, Sweden), C. Stridsman (Umeå, Sweden), E. Rönmark (Umeå, Sweden)
| |
Outpatient smoking cessation: preliminary findings of a non-inferiority RCT comparing blended with face-to-face delivery mode
L. Siemer (Enschede, Netherlands), M. Pieterse (Enschede, Netherlands), S. Ben Allouch (Amsterdam, Netherlands), M. Postel (Enschede, Netherlands), R. Sanderman (Groningen, Netherlands), M. Brusse-Keizer (Enschede, Netherlands)
| |
Flavor-solvent reaction products in electronic cigarette liquids activate respiratory irritant receptors and elicit cytotoxic metabolic responses in airway epithelial cell
S. Jordt (Durham, NC, United States of America), A. Caceres (Durham, NC, United States of America), H. Erythropel (New Haven, CT, United States of America), J. Zimmerman (New Haven, CT, United States of America), T. Dewinter (New Haven, CT, United States of America), S. Jabba (Durham, NC, United States of America)
| |
Multiple-breath washout and pulmonary function tests versus high-resolution computed tomography scores in adults with cystic fibrosis.
A. Cherniak (Moscow, Russian Federation), Z. Naumenko (Moscow, Russian Federation), S. Krasovskiy (Moscow, Russian Federation), K. Mikhailichenko (Moscow, Russian Federation), G. Nekludova (Moscow, Russian Federation)
| |
Air liquid interface (ALI)-grown immortalized human cell lines: a promising tractable model for human airway
Z. Alharbi (Sheffield, United Kingdom), M. Chowdhury (Sheffield, United Kingdom), L. Bingle (Sheffield, United Kingdom), C. Bingle (Sheffield, United Kingdom)
| |
Late Breaking Abstract - ACE2 expression in lower airway epithelial cells is increased with age and in males, but is less in asthma.
P. Wark (Newcastle (NSW), Australia), P. Pathinyake (New Lambton Heights (NSW), Australia), G. Kaiko (Newcastle, Australia), S. Sohal (Launceston (TAS), Australia), C. Oldmeadow (Newcastle, Australia), N. Bartlett (Newcastle, Australia), S. Stick (Perth, Australia), P. Hansbro (Sydney (NSW), Australia), A. Kicic (NPerth (WA), Australia)
| |
Late Breaking Abstract - Organoids and lung-on-chip to study SARS-CoV-2-mediated lung injury
M. Kiener (Bern, Switzerland), L. De Maddalena (Bern, Switzerland), N. Roldan (Bern, Switzerland), G. Thalmann (Bern, Switzerland), T. Geiser (Bern, Switzerland), N. Hobi (Bern, Switzerland), M. Kruithof-De Julio (Bern, Switzerland)
| |
Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
J. Chalmers (Dundee (Angus), United Kingdom), D. Cipolla (Hayword, United States of America), B. Thompson (Owings Mills, United States of America), A. Davis (Clayton, United States of America), A. O'Donnell (Washington, United States of America), G. Tino (Philadelphia, United States of America), I. Gonda (Hayward, United States of America), C. Haworth (Cambridge, United Kingdom), J. Froehlich (Hayward, United States of America)
| |
Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study
J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America)
| |
Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study
M. Loebinger (London, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), S. Elborn (Belfast, United Kingdom), J. Chalmers (Scotland, United Kingdom), H. Tiddens (Rotterdam, Netherlands), H. Goossens (Antwerp, Belgium), M. Tunney (Belfast, United Kingdom), F. Ringshausen (Hannover, Germany), A. Hill (Edinburgh, United Kingdom), R. Pathan (Hyderabad, India), G. Angyalosi (Basel, Switzerland), C. Haworth (Cambridge, United Kingdom)
| |
Is smoking a major risk factor for COVID-19 infection and severe disease?
F. Filippidis (Oxford, United Kingdom)
| |
Asthma, atopy and lung function in young adults hospitalised for bronchiolitis in infancy.
K. Sørensen (Stavanger, Norway), K. Øymar (Stavanger, Norway), T. Halvorsen (Bergen, Norway), I. Mikalsen (Stavanger, Norway)
| |
Padiatric Asthma in Canada 2016: A cross-sectional study in primary care
A. Cave (Edmonton, Canada), C. Gillies (Edmontonnton (AB), Canada), S. Aponte-Hao (Calgary, Canada), B. Soos (Calgary, Canada), T. Williamson (Calgary, Canada), N. Drummond (Edmonton, Canada)
| |
The role of eosinophils in pediatric and adult asthma
J. Omony (Neuherberg, Germany), R. Grychtol (Hannover, Germany), N. Maison (Munich, Germany), D. Thiele (Lübeck, Germany), A. Chari Jirmo (Hannover, Germany), A. Dittrich (Hannover, Germany), T. Bahmer (Grosshansdorf, Germany), K. Rabe (Grosshansdorf, Germany), H. Renz (Marburg, Germany), G. Hansen (Hannover, Germany), M. Kopp (Lübeck, Germany), B. Schaub (Munich, Germany), E. Von Mutius (Neuherberg, Germany), S. Illi (Neuherberg, Germany)
| |
Identification of important respiratory research themes relevant to primary care: qualitative analysis of round 1 of the 2020 International Primary Care Respiratory Group (IPCRG) Research Prioritisation Exercise
A. Abdel-Aal (Hull/ York, United Kingdom), R. Jordan (Birmingham, United Kingdom), P. Adab (Birmingham, United Kingdom), R. Adam (Birmingham, United Kingdom), A. Barnard (Sydney, Australia), I. Bouloukaki (Crete, Greece), J. Boven (Groningen, Netherlands), N. Chavannes (Leiden, Netherlands), A. Dickens (Birmingham, United Kingdom), F. Gemert (Groningen, Netherlands), M. Escarrer (Mallorca, Spain), S. Haroon (Birmingham, United Kingdom), A. Kayongo (Kampala, Uganda), B. Kirenga (Kampala, Uganda), J. Kocks (Groningen, Netherlands), D. Kotz (Düsseldorf, Germany), K. Lisspers (Uppsala, Sweden), C. Newby (London, United Kingdom), C. Mcnulty (Gloucester, United Kingdom), E. Metting (Groningen, Netherlands), L. Moral (Alicante, Spain), S. Papadakis (Ottawa, Canada), H. Pinnock (Edinburgh, United Kingdom), D. Price (Singapore, Singapore), D. Ryan (Edinburgh, United Kingdom), S. Singh (Leicester, United Kingdom), J. Sousa ( Porto, Portugal), B. Ställberg (Uppsala, Sweden), S. Szefler (Colorado, United States of America), S. Taylor (London, United Kingdom), I. Tsiligianni (Crete, Greece), A. Turner (Birmingham, United Kingdom), D. Weller (Edinburgh, United Kingdom), S. Williams (England, United Kingdom)
| |
Comparison of first experience with different inhalers in COPD: a cross-over study
H. Harb (Beni-Suef, Egypt), N. Laz (Beni-Suef, Egypt), H. Rabea (Beni-Suef, Egypt), M. Abdelrahim (Beni-Suef, Egypt)
| |
The impact of different valved holding chambers (VHCs) on lung drug delivery: using functional respiratory imaging (FRI) and a single metered dose inhaler (MDI) type
J. Suggett (London (ON), Canada), V. Kushnarev (London (ON), Canada), C. Van Holsbeke (Kontich, Belgium), S. Van Steen (Kontich, Belgium), B. Mignot (Kontich, Belgium)
| |
Immundefects, rare pulmonary infections and rare lung diseases
J. Hurst (London, United Kingdom)
| |
Lung function in extremely preterm born adults over three decades
T. Bårdsen (Bergen, Norway), M. Benestad (Bergen, Norway), O. Røksund (Bergen, Norway), H. Clemm (Bergen, Norway), I. Mikalsen (Stavanger, Norway), K. Øymar (Stavanger, Norway), T. Halvorsen (Bergen, Norway), M. Vollsæter (Bergen, Norway)
| |
The best papers in the ERJ: chronic airways diseases, including asthma and COPD
M. Gaga (Athens, Greece)
| |
Comorbidities in asthma: the role of obesity in children with asthma
E. Forno (Pittsburgh, United States of America)
| |
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
L. Fleming (London, United Kingdom)
| |
Effect of nocturnal oxygen therapy on next-day exercise performance of COPD patients at 2048m. Data from a RCT.
S. Gutweniger (Zürich, Switzerland), T. Latshang (Zürich, Switzerland), S. Aeschbacher (Zürich, Switzerland), F. Huber (Zürich, Switzerland), D. Flueck (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland), E. Hasler (Zürich, Switzerland), P. Scheiwiller (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), M. Furian (Zürich, Switzerland)
| |
Effect of High-Flow Oxygen on Exercise Performance In COPD. A Randomized Crossover Trial.
K. Bitos (Zurich, Switzerland), M. Furian (Zurich, Switzerland), L. Mayer (Zurich, Switzerland), S. Schneider (Zurich, Switzerland), S. Buenzli (Zurich, Switzerland), M. Mademilov (Bishkek, Kyrgyzstan), U. Sheraliev (Bishkek, Kyrgyzstan), A. Abdraeva (Bishkek, Kyrgyzstan), S. Aydaralieva (Bishkek, Kyrgyzstan), A. Myratbekova (Bishkek, Kyrgyzstan), T. Sooronbaev (Bishkek, Kyrgyzstan), S. Ulrich (Zurich, Switzerland), K. Bloch (Zurich, Switzerland)
| |
Altered exhaled NO parameters in newly onset of rheumatoid arthritis
M. Högman (Uppsala, Sweden), A. Thornadtsson (Uppsala, Sweden), A. Lind (Gävle, Sweden), T. Weitoft (Gävle, Sweden)
| |
An international perspective on the demographic and clinical features of exercise induced laryngeal obstruction
E. Walsted (Copenhagen, Denmark), B. Famokunwa (Bristol, United Kingdom), L. Andersen (Aarhus, Denmark), S. Rubak (Aarhus, Denmark), F. Buchvald (Copenhagen, Denmark), L. Pedersen (Copenhagen, Denmark), J. Dodd (Bristol, United Kingdom), V. Backer (Copenhagen, Denmark), K. Nielsen (Copenhagen, Denmark), A. Getzin (Ithaca, NY, United States of America), J. Hull (London, United Kingdom)
| |
PIERCEing ciliogenesis: defining a role for PIERCE1 and its’ paralog C15ORF65 in multiciliogenesis
M. Chowdhury (Sheffield, United Kingdom), P. Anujan (Sheffield, United Kingdom), L. Bingle (Sheffield, United Kingdom), C. Bingle (Sheffield, United Kingdom)
| |
Activity of ENaC-activating serine proteases in human alveolar epithelial cells
A. Tavakolinejad (Auckland, New Zealand), V. Suresh (Auckland, New Zealand)
| |
The effect of Taxane anticancer drugs on bronchiolar ciliary activity in human airway cultured cells
N. Tamiya (Kyoto, Japan), S. Hosogi (Kyoto, Japan), J. Suzumoto (Kyoto, Japan), M. Ishida (Kyoto, Japan), C. Sakaguchi (Kyoto, Japan), M. Tsuchiya (Kyoto, Japan), Y. Nagasaka (Kyoto, Japan), E. Ashihara (Kyoto, Japan), K. Takayama (Kyoto, Japan)
| |